A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
Price : $35 *
At a glance
- Drugs Roxadustat (Primary) ; Epoetin alfa; Epoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors FibroGen
- 30 Mar 2017 Results from this trial were published in Nephrology Dialysis Transplantation, according to a FibroGen media release.
- 30 Mar 2017 Results published in a FibroGen media release.
- 30 Mar 2017 Primary endpoint (Haemoglobin level (Number of patients whose haemoglobin levels are maintained at no lower than 0.5 g/dL below their mean baseline value during weeks 6 and 7.)) has been met, according to a FibroGen media release.